Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Biomarker Study of ATH434 in Multiple System Atrophy

Next Previous
X
Search
Trial Profile

An Open-Label Biomarker Study of ATH434 in Multiple System Atrophy

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Feb 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ATH 434 (Primary)
  • Indications Multiple system atrophy
  • Focus Biomarker; Therapeutic Use
  • Sponsors Alterity Therapeutics

    • Most Recent Events

    • 10 Feb 2025 According to an Alterity Therapeutics media release, company announced that it has received binding commitments for a capital raising of A$40.0 million via a two tranche placement to Australian and international institutions and other unrelated sophisticated, professional or exempt investors. Funds to be used primarily to advance development of ATH434 .
    • 22 Nov 2024 According to an Alterity Therapeutics media release, company expect to deliver the full results of this 202 trial in the first half of calendar year 2025.
    • 01 Nov 2024 According to an Alterity Therapeutics media release, company is looking forward to presenting additional data at medical meetings, and positive interim data from ATH434-202 trial in calendar year 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top